Advancing to Human Trials as the Outbreak Clock Ticks: First Bundibugyo Ebola Vaccine Dose Administered in Oxford

As the Bundibugyo Ebola virus spreads in the Democratic Republic of the Congo and Uganda, disease-control systems face a difficult gap: existing Ebola vaccines are not authorized for use against this virus type. The University of Oxford has now administered the first human dose of the ChAdOx1 BDBV vaccine candidate, moving development from the laboratory into the clinic; *Nature* noted that this came just 68 days after the World Health Organization declared a public health emergency of international concern.

The first vaccine dose was administered in Oxford, United Kingdom, on July 24. Agence France-Presse reported that the participant was 37-year-old Ed Hunt. This is not a direct test of protective efficacy in an outbreak area, but a Phase 1, first-in-human trial named BD-Ebov-01. It is expected to enroll 50 healthy adults aged 18 to 55 and will primarily evaluate safety, tolerability, and whether the vaccine can induce the expected immune response.

According to the trial registry, the study will first vaccinate 10 people on an open-label basis to enable close examination of early reactions. Another 40 participants will then be randomly assigned in a 3:1 ratio to receive either the vaccine or a saline placebo. The first group of participants is also scheduled to receive an exploratory booster dose six months later to assess the feasibility of revaccination and the resulting immune response, but these study designs remain insufficient to determine real-world efficacy in preventing disease.

ChAdOx1 BDBV uses a chimpanzee adenovirus vector platform and follows a technological approach similar to that of the Oxford–AstraZeneca COVID-19 vaccine. The manufacturing and clinical experience accumulated with the platform has helped the team shorten the time required for design, material preparation, and trial initiation. The study is sponsored by the University of Oxford and funded by the Coalition for Epidemic Preparedness Innovations, CEPI.

Beyond speed, the team has also prepared supplies in advance. According to Agence France-Presse, the Serum Institute of India has manufactured a stockpile of 620,000 doses. However, having vaccine supplies does not mean that large-scale vaccination can begin immediately. The candidate vaccine must still receive authorization from regulators and demonstrate preliminary safety and immunogenicity before subsequent studies could begin in locations including Uganda. If early results support continued development, later-stage trials could then have the opportunity to accumulate the evidence required for emergency use or full approval.

Background

The Bundibugyo type is one of the Ebola viruses that less frequently causes outbreaks, and there is currently no approved vaccine or specific treatment targeting it. The World Health Organization has listed ChAdOx1 BDBV and the rVSV Bundibugyo vaccine candidate developed by IAVI as priorities for clinical evaluation during the outbreak, indicating that the current strategy aims not only for speed but also to avoid placing disease-control hopes on a single technological approach.

The significance of this first vaccination is that it demonstrates the candidate vaccine can rapidly enter human testing while an outbreak is evolving quickly, not that it has already been shown to contain the outbreak. The trial is small, its participants are healthy adults in the United Kingdom, and it does not yet include populations in outbreak areas, children, or people at high risk of exposure. Protective efficacy, rare adverse effects, the duration of immunity, and effectiveness when deployed in the field all remain to be answered by larger subsequent studies.